Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perz, J.
Right arrow Articles by Olavarria, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perz, J.
Right arrow Articles by Olavarria, E
Haematologica, Vol 91, Issue 8, 1145-1146
Copyright © 2006 by Ferrata Storti Foundation

Letter

Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia

JB Perz, JS Khorashad, D Marin, JF Apperley, and E Olavarria

In 37 adults with chronic myeloid leukemia undergoing allogeneic stem cell transplantation imatinib prior to transplant had no discernible negative impact on 100-day mortality (13%) and severe acute (22%) or extensive chronic graft-versus- host disease (31%). After a median of 203 days (range: 18-1419) overall and progression-free survival rates are 62% and 54%, respectively.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.